The invention is directed to pharmaceutical compositions such as tablets that exhibit delayed release properties when administered as either whole or half tablets. The invention is also directed to delayed release tablets comprising deferiprone for oral administration, for which twice daily administration is bioequivalent to the same daily dose of an immediate release tablet administered thrice daily. The invention is also directed to methods of making and using the same.

A nanoparticle ATQ composition is provided which has good stability and bioavailability. Compositions and methods of using the nanoparticle ATQ composition in treating parasitic and other infections is described.

Hydrodynamic methods for conformally coating non-uniform size cells and cell clusters for implantation, thus preventing immune rejection or inflammation or autoimmune destruction while preserving cell functionality. A method for conformally coating cells and cell clusters with hydrogels that are biocompatible, mechanically and chemically stable and porous, with an appropriate pore cut-off size. The methods of the invention are advantageously reproducible and result in a relatively high yield of coated versus non-coated cell clusters, without compromising cell functionality. Conformal coating devices configured to perform the methods of the invention, methods of optimally utilizing said devices and purifying the coated islets, and coated biomaterials made by said methods.

The present invention relates to a hygroscopic matrix based composition, a process for the preparation thereof and its use in the treatment of diseases.

The present invention relates to directly compressible co-mixtures for the production of tablets having delayed release of active compound which comprise polyvinyl alcohols (PVAs) and microcrystalline celluloses (MCCs). The invention also relates to a process for the preparation of corresponding directly compressible co-mixture

The invention relates to novel hydrates of dolutegravir sodium and to processes for their preparation. Furthermore, the invention relates to a novel crystalline form of dolutegravir sodium, which is a useful intermediate for the preparation of one of the novel hydrates. In addition, the invention relates to the use of the novel hydrates for the production of pharmaceutical compositions. Finally, the invention relates to pharmaceutical compositions comprising an effective amount of the novel hydrates, to oral dosage forms comprising said pharmaceutical compositions, to a process for preparing said oral dosage forms, and to the use of said pharmaceutical compositions or dosage forms in the treatment of retroviral infections such as HIV-1 infections.

##STR00001##

An oral formulation, and preparation method and use thereof; the oral formulation comprises 1-50 parts by weight of an A-nor-5a-androstane compound, 20-95 parts by weight of a filling agent, 0-20 parts by weight of a disintegrant, 0.1-30 parts by weight of a binder, 0.1-5 parts by weight of a lubricant and 0.1-5 parts by weight of a glidant. The oral formulation has a high stability and a good dissolution performance.

An object of the present invention is to provide a pharmaceutical composition comprising 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof at a high concentration, with a characteristic bitter taste masked, and a manufacturing method thereof. The present invention provides a pharmaceutical composition comprising fine granules having a core comprising 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof, and a binder; and a polymer layer with which a surface of the core is coated, wherein the fine granules have a roundness of 0.8 or more and a content of 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or the salt thereof in the fine granules is 30 to 90% by mass.

Provided herein is an amorphous compound represented by Formula (I):

##STR00001##

and compositions thereof, which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFRα kinases, and oncogenic forms thereof.

A compact sustained release tablet comprising divalproex or its pharmaceutically acceptable salts as a sole active ingredient is present in an amount equivalent to from about 700 mg to about 1500 mg of valproic acid and pharmaceutically acceptable tablet excipients; wherein weight ratio of pharmaceutically acceptable tablet excipients to divalproex and/or its salt is less than 1, the tablet is suitable for once a day administration and when orally administered, with or without food, the ratio of mean AUC.sub.0.sub._.sub.inf-fasted to mean AUC.sub.0.sub._.sub.inf-fed is within the range of 0.9 to 1.1.